CYP1A1 Msp1 T/C polymorphism in esophageal cancer: No association and risk modulation

Oncology Research

Volumn 16, Issue 9, 2007, Pages 437-443

  Jain, Meenu ^a   Kumar, Shaleen ^a   Ghoshal, Uday C ^a   Mittal, Balraj ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

CYP1A1; Esophageal cancer; Polymorphisms; Risk

Indexed keywords

CYTIDINE; CYTOCHROME P450 1A1; MEROZOITE SURFACE PROTEIN 1; THYMIDINE;

3' UNTRANSLATED REGION; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INDIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION; AGED; ENVIRONMENTAL EXPOSURE; ESOPHAGUS TUMOR; GENETICS; MIDDLE AGED; RISK;

3' UNTRANSLATED REGIONS; ADULT; AGED; CYTOCHROME P-450 CYP1A1; ENVIRONMENTAL EXPOSURE; ESOPHAGEAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK;

EID: 38449101981     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000007783980846     Document Type: Article

References (27)

1. Munoz, N. Epidemiological aspects of oesophageal cancer. Endoscopy 25:609-612; 1993.
2. Importance of anatomical subsite in correlating risk factors in cancer of the esophagus - report of a case-control study. Br. J. Cancer 73:1306-1311; 1996.
3. Lakehal, F.; Wendum, D.; Barbu, V.; Becquemont, L.; Poupon, R.; Balladur, P.; Hannoun, L.; Ballet, F.; Beaune, P. H.; Housset, C. Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium. Hepatology 30:1498-1506; 1999.
4. El-Rayes, B. F.; Ali, S.; Heilbrun, L. K.; Lababidi, S.; Bouwman, D.; Visscher, D.; Philip, P. A. Cytochrome p450 and glutathione transferase expression in human breast cancer. Clin. Cancer Res. 9:1705-1709; 2003.
5. Murray, G. I.; Shaw, D.; Weaver, R. J.; McKay, J. A.; Ewen, S. W.; Melvin, W. T.; Burke, M. D. Cytochrome P450 expression in oesophageal cancer. Gut 35:599-603; 1994.
6. Lechevrel, M.; Casson, A. G.; Wolf, C. R.; Hardie, L. J.; Flinterman, M. B.; Montesano, R.; Wild, C. P. Characterization of cytochrome P450 expression in human esophageal mucosa. Carcinogenesis 20:243-248; 1999.
7. Sato, M.; Sato, T.; Izumo, T.; Amagasa, T. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis 20:1927-1931; 1999.
8. Landi, M.; Bertazzi, T.; Shields, P.; Clark, P.; Lucier, G.; Garte, S.; Cosma, G.; Caporaso, N. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 4:242-246; 1994.
9. Cascorbi, I.; Brockmoller, J.; Roots, I. A. C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 56:4965-4969; 1996.
10. Wang, L. D.; Zheng, S.; Liu, B.; Zhou, J. X.; Li, Y. J.; Li, J. X. CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: Study of population from a high- incidence area in north China. World J. Gastroenterol. 9:1394-1397; 2003.
11. Li, Y.; Millikan, R. C.; Bell, D. A.; Cui, L.; Tse, C. K.; Newman, B.; Conway, K. Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among African-American and white women. Breast Cancer Res. 6: R460-473; 2004.
12. van Lieshout, E. M.; Roelofs, H. M.; Dekker, S.; Mulder, C. J.; Wobbes, T.; Jansen, J. B.; Peters, W. H.; Hori, H.; Kawano, T.; Endo, M.; Yuasa, Y.; Nimura, Y.; Yokoyama, S.; Fujimori, M.; Aoki, T.; Adachi, W.; Nasu, T.; He, M.; Ping, Y. M.; Iida, F.; Morita, S.; Yano, M.; Shiosaki, H.; Tsujinaka, T.; Ebisui, C.; Morimoto, T.; Kishibuti, M.; Fujita, J.; Ogawa, A.; Taniguchi, M.; Inoue, M.; Tamura, S.; Yamazaki, K.; Kikkawa, N.; Mizunoya, S.; Monden, M.; Lucas, D.; Menez, C.; Floch, F.; Gourlaouen, Y.; Sparfel, O.; Joannet, I.; Bodenez, P.; Jezequel, J.; Gouerou, H.; Berthou, F.; Bardou, L. G.; Menez, J. F.; Murray, G. I.; Shaw, D.; Weaver, R. J.; McKay, J. A.; Ewen, S. W.; Melvin, W. T.; Burke, M. D.; Carstensen, U.; Alexandrie, A. K.; Hogstedt, B.; Rannug, A.; Bratt, I.; Hagmar, L. Polymorphic expression of the glutathione Stransferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. Cancer Res. 59: 586-589; 1999.
13. Yang, C. X.; Matsuo, K.; Wang, Z. M.; Tajima, K. Phase I/II enzyme gene polymorphisms and esophageal cancer risk: A meta-analysis of the literature. World J. Gastroenterol. 11:2531-2538; 2005.
14. Jain, M.; Kumar, S.; Lal, P.; Tiwari, A.; Ghoshal, U. C.; Mittal, B. Role of GSTM3 polymorphism in the risk of developing esophageal cancer. Cancer Epidemiol. Biomarkers Prev. 16:178-181; 2007.
15. Kawajiri, K.; Nakachi, K.; Imai, K.; Shinoda, N.; Watanabe, J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett. 263:131-133; 1990.
16. Launoy, G.; Milan, C.; Day, N. E.; Faivre, J.; Pienkowski, P.; Gignoux, M. Oesophageal cancer in France: Potential importance of hot alcoholic drinks. Int. J. Cancer 71:917-923; 1997.
17. Kiyohara, C.; Wakai, K.; Mikami, H.; Sido, K.; Ando, M.; Ohno, Y. Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: A case-control study in Japanese nonsmoking women. Int. J. Cancer 107:139-144; 2003.
18. Garte, S.; Gaspari, L.; Alexandrie, A. K.; Ambrosone, C.; Autrup, H.; Autrup, J. L.; Baranova, H.; Bathum, L.; Benhamou, S.; Boffetta, P.; Bouchardy, C.; Breskvar, K.; Brockmoller, J.; Cascorbi, I.; Clapper, M. L.; Coutelle, C.; Daly, A.; Dell'Omo, M.; Dolzan, V.; Dresler, C. M.; Fryer, A.; Haugen, A.; Hein, D. W.; Hildesheim, A.; Hirvonen, A.; Hsieh, L. L.; Ingelman-Sundberg, M.; Kalina, I.; Kang, D.; Kihara, M.; Kiyohara, C.; Kremers, P.; Lazarus, P.; Le Marchand, L.; Lechner, M. C.; van Lieshout, E. M.; London, S.; Manni, J. J.; Maugard, C. M.; Morita, S.; Nazar-Stewart, V.; Noda, K.; Oda, Y.; Parl, F. F.; Pastorelli, R.; Persson, I.; Peters, W. H.; Rannug, A.; Rebbeck, T.; Risch, A.; Roelandt, L.; Romkes, M.; Ryberg, D.; Salagovic, J.; Schoket, B.; Seidegard, J.; Shields, P. G.; Sim, E.; Sinnet, D.; Strange, R. C.; Stucker, I.; Sugimura, H.; To-Figueras, J.; Vineis, P.; Yu, M. C.; Taioli, E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 10:1239-1248; 2001.
19. Mittal, R. D.; Srivastava, D. S.; Mandhani, A.; et al. Genetic polymorphism of drug metabolizing enzymes (CYP2E1, GSTP1) and susceptibility to bladder cancer in North India. Asian Pac. J. Cancer Prev. 6:6-9; 2005.
20. Hori, H.; Kawano, T.; Endo, M.; Yuasa, Y. Genetic polymorphisms of tobacco and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J. Clin. Gastroenterol. 25:568-575; 1997.
21. Lin, D. X.; Tang, Y. M.; Peng, Q.; Lu, S. X.; Ambrosone, C. B.; Kadlubar, F. F. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol. Biomarkers. Prev. 7:1013-1018; 1998.
22. Wu, M. T.; Lee, J. M.; Wu, D. C.; Ho, C. K.; Wang, Y. T.; Lee, Y. C.; Hsu, H. K.; Kao, E. L. Genetic polymorphisms of cytochrome P4501A1 and oesophageal squamous-cell carcinoma in Taiwan. Br. J. Cancer 87: 529-532; 2002.
23. Casson, A. G.; Zheng, Z.; Chiasson, D.; MacDonald, K.; Riddell, D. C.; Guernsey, J. R.; McLaughlin, J. Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect. Prev. 27:139-146; 2003.
24. Morita, S.; Yano, M.; Shiozaki, H.; Tsujinaka, T.; Ebisui, C.; Morimoto, T.; Kishibuti, M.; Fujita, J.; Ogawa, A.; Taniguchi, M.; Inoue, M.; Tamura, S.; Yamazaki, K.; Kikkawa, N.; Mizunoya, S.; Monden, M. CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus. Int. J. Cancer 71:192-195; 1997.
25. Monteiro, E.; Varzim, G.; Pires, A. M.; Teixeira, M.; Lopes, C. Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cell carcinoma: Implications of tumor localization and tobacco exposure. Cancer Detect. Prev. 28:237-243; 2004.
26. Engel, L. S.; Chow, W. H.; Vaughan, T. L.; Gammon, M. D.; Risch, H. A.; Stanford, J. L.; Choenberg, J. B.; Mayne, S. T.; Dubrow, R.; Rotterdam, H.; West, A. B.; Blaser, M.; Blot, W. J.; Gail, M. H.; Fraumeni, Jr., J. F. Population attributable risks of esophageal and gastric cancers. J. Natl. Cancer Inst. 95:1404-1413; 2003.
27. Carstensen, U.; Alexandrie, A. K.; Hogstedt, B.; Rannug, A.; Bratt, I.; Hagmar, L. B and T lymphocyte micronuclei in chimney sweeps with respect to genetic polymorphism for CYP1A1 and GST1 (class Mu). Mutat. Res. 289:187-195; 1993.